Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this multicenter retrospective study, 61.5% of Italian patients with severe alopecia areata achieved significant hair improvement after 52 weeks of treatment with baricitinib, with no major safety issues reported, indicating long-term effectiveness in a real-world setting.

This study found that patients with severe alopecia areata who experienced meaningful scalp hair regrowth showed greater improvements in health-related quality of life and reduced anxiety and depression compared to those with no or minimal regrowth.

This study evaluated baricitinib 4 mg treatment in severe to very severe alopecia areata, reporting significant scalp hair regrowth by Week 52, especially in short-duration episodes, suggesting treatment should continue for at least a year before assessing failure.

This study identified a unique circulating microRNA signature associated with severe alopecia areata, distinguishing it from other inflammatory skin conditions and suggesting these miRNAs as non-invasive biomarkers for diagnosis and potential therapeutic targets.

This study demonstrated the high effectiveness and safety of tofacitinib, a pan-JAK inhibitor, in treating severe forms of alopecia areata, although it is not yet FDA-approved for this condition.

In this study, researchers found that patients with severe alopecia areata who respond to baricitinib treatment within six months may improve clinically within a year, while those with very severe disease may require at least a year for evidence of treatment effect.

In a Belgian cohort study, nearly 90% of alopecia areata patients treated with oral baricitinib experienced hair regrowth, with more than 70% achieving a favorable SALT score, particularly in patchy cases, though some relapsed post-treatment. No serious adverse events were noted.

This study found that both ruxolitinib and tofacitinib were effective in promoting hair regrowth for patients with severe alopecia areata, with no significant difference in efficacy and relapse rate between them, and both were well tolerated throughout the treatment.

In this retrospective study, tofacitinib was found to be effective and well-tolerated for treating severe alopecia areata, with 77% of patients achieving a clinical response over 4-20 months, though results were more favorable for patients with less extensive hair loss.

This retrospective study found that methotrexate had variable efficacy in treating severe alopecia areata in children, with successful hair regrowth observed in five out of thirteen assessable cases.

This study describes a case where a 2-year-old girl with severe alopecia areata showed marked hair regrowth after 37 weeks of treatment with dupilumab and minoxidil, but due to concurrent therapies and potential spontaneous recovery, improvements cannot solely be attributed to dupilumab.

This narrative review found that post-COVID-19 hair loss, particularly telogen effluvium, poses a significant mental and social burden, with minoxidil potentially aiding recovery, although more clinical research is needed to confirm its effectiveness.

CD8+ T cells re-expressing CD45RA may predict treatment resistance in severe alopecia areata.

This study explored the effectiveness of the oral JAK1/2 inhibitor ruxolitinib in treating patients with moderate-to-severe alopecia areata, building on prior success with JAK inhibitors in mice, but results are not reported in this abstract.

This article discusses the autoimmune pathogenesis of alopecia areata and reviews the use of immunosuppressive therapies in its treatment, but it does not provide new clinical results.

This study found that combining topical and oral pulse corticosteroid therapy for severe alopecia areata in children led to long-lasting hair regrowth, especially in AA plurifocalis, with no serious side effects reported.

This study found that monthly high-dose steroid pulse therapy for approximately six months was effective and well-tolerated in Taiwanese patients with severe multifocal alopecia areata.

This study reports that sequential high- and low-dose prednisolone therapy effectively promotes complete hair regrowth in 62% of children with severe alopecia areata, while minimizing severe side effects.

Wigs significantly improve the well-being of people with severe hair loss.

This article is a letter to the editor about high-dose pulsed corticosteroid therapy combined with methotrexate for severe childhood alopecia areata and provides no new clinical results.

This study found that tofacitinib is an effective and more tolerable treatment than systemic corticosteroids for moderate-to-severe alopecia areata, and its combination with corticosteroids may offer improved efficacy.

This retrospective cohort study found no significant association between Janus kinase inhibitors and increased malignancy risk in alopecia areata patients, but traditional immunosuppressants were linked to higher risks of internal and hematologic malignancies.

This study focused on baricitinib's effect on patients with severe alopecia areata, highlighting its efficacy for hair regrowth and its potential to improve health-related quality of life and psychological symptoms, as seen in two phase 3 trials.

Mini pulse corticosteroid therapy with oral dexamethasone is effective and has fewer side effects for treating extensive alopecia areata.

In this study, baricitinib 4 mg led to greater scalp, eyebrow, and eyelash hair regrowth in severe alopecia areata patients than baricitinib 2 mg at weeks 36 and 52.

This review discusses various treatment options for Alopecia Areata, focusing on both medical and psychological approaches, and reports no new clinical results.

The measures for eyebrow and eyelash hair loss in severe Alopecia Areata are reliable and useful for clinical trials.

This review discusses the use of Janus kinase inhibitors for severe alopecia areata in Japan, noting their effectiveness in some patients but highlighting the need for new therapies due to non-responsiveness and relapse in others; it reports no new clinical results.

This study reviewed a corticosteroid treatment regimen for a 52-year-old woman with extensive alopecia areata, showing significant hair regrowth and sustained remission over 12 months, suggesting oral mini-pulse therapy as a viable alternative for those ineligible for JAK inhibitors.

IMG-007 helps regrow hair and reduce scalp inflammation in severe alopecia areata.